News: CSL UPDATE 1-Biotech firm CSL's full-year profit rises on higher plasma collections, page-3

Here’s a simple breakdown from AFR:


Blood products giant CSL has lifted full-year underlying profit 10 per cent to $US2.61 billion ($4 billion) after a surge in sales of its core immunoglobulin division led by blockbuster therapies Privigen and Hizentra.

Underlying net profit after tax and amortisation at constant currencies was up 20 per cent, showing a strong rebound from pandemic troubles in its core CSL Behring business of immunoglobulin-based treatments for chronic immune system deficiencies.

Earnings per share grew just 6 per cent to $US5.41 (17 per cent at constant currencies) and the company declared a final dividend of $US1.29 a share, making $US2.36 in total dividends (up 6 per cent), or $3.59 a share for Australian shareholders.

Chief executive Paul McKenzie, who took over from Paul Perreault in March, said CSL Behring had “rebounded strongly driven by exceptional growth in immunoglobulin sales and record plasma collections”.

It was in the middle of CSL’s guidance for full-year net profit after tax and amortisation of $US2.7 billion to $US2.8 billion at constant currencies.